ELCA Coronary Atherectomy Catheters
Spectranetics Corp. · Decision date Feb 6, 2026
What did the FDA approve?
FDA records P910001/S124 as a supplement to PMA P910001, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Feb 6, 2026.
FDA approval order statement
the use of alternate components in the adhesive supplied to Philips/Spectranetics for the sterile barrier of the packaging system
- Regulatory pathway
- PMA supplement
- Supplement type
- 135 Review Track For 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Feb 6, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P910001/S124
- Regulatory pathway
- PMA supplement
- Applicant
- Spectranetics Corp.
- Product code
- LPC
- Decision code
- APPR
- Decision date
- Feb 6, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: DEVICE, ANGIOPLASTY, LASER, CORONARY.
- Applicant
- Spectranetics Corp.
- Product code
- LPC
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P910001/S124 received
Application receipt date recorded by FDA.
P910001/S125 · Related supplement
ELCA Coronary Atherectomy Catheters
P910001/S124 · FDA decision
135 Review Track For 30-Day Notice
P910001/S126 · Related supplement
ELCA Coronary Laser Atherectomy Catheters
P910001/S127 · Related supplement
Philips Laser System
Timeline entries are records held by MedtechLedger for P910001. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P910001
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ELCA Coronary Atherectomy CathetersP910001/S125 | Spectranetics Corp. | PMA supplement | Dec 18, 2025 | FDA |
ELCA Coronary Laser Atherectomy CathetersP910001/S126 | Spectranetics Corp. | PMA supplement | Aug 14, 2026 | FDA |
Philips Laser SystemP910001/S127 | Spectranetics Corp. | PMA supplement | Aug 21, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Spectranetics Corp.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 9965 Federal Dr., Colorado Springs, CO, 80921
Sources and methodology
- Original FDA record: P910001/S124
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records
